BioMarin Pharmaceutical to Acquire Alesta Therapeutics for $275 Million to Develop Oral Treatment for Rare Bone Disease
BioMarin Pharmaceutical's acquisition of Alesta Therapeutics for $275 million marks a strategic move to enhance its portfolio in rare diseases, particularly targeting hypophosphatasia (HPP). This deal underscores BioMarin's commitment to addressing unmet medical needs in the rare disease market.